Tumor gangliosides and T cells: A deadly encounter

Frontiers in Bioscience - Scholar

Volumn 4 S, Issue 2, 2012, Pages 502-519

  Hossain, Dewan Md Sakib ^a   Mohanty, Suchismita ^a   Ray, Pallab ^a   Das, Tanya ^a   Sa, Gaurisankar ^a  

^a BOSE INSTITUTE   (India)

Author keywords

Apoptosis; Gangliosides; Immunesuppression; Review; T lymphocytes; Tumor

Indexed keywords

CERAMIDE; CYTOCHROME C; GALACTOSAMINE; GALACTOSE; GANGLIOSIDE; GLUCOSE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 2; REACTIVE OXYGEN METABOLITE; SIALIC ACID; TUMOR GANGLIOSIDE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CELL SURVIVAL; DENDRITIC CELL; HUMAN; LIPOGENESIS; NATURAL KILLER CELL; NEOPLASM; NONHUMAN; PROTEIN SECRETION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TH17 CELL; TH2 CELL; TUMOR ESCAPE; ANIMAL; CELL COMMUNICATION; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IMMUNOTHERAPY; REVIEW;

ANIMALS; CELL COMMUNICATION; GANGLIOSIDES; HUMANS; IMMUNE TOLERANCE; IMMUNOTHERAPY; NEOPLASMS; T-LYMPHOCYTES;

EID: 84864586002     PISSN: 19450516     EISSN: 19450524     Source Type: Journal    
DOI: None     Document Type: Article

References (127)

1. S Bhattacharyya. D Mandal, B Saha. GS Sen, T Das, G Sa: Curcumin prevents tumor-induced T cell apoptosis through Stat-5a-mediated Bcl-2 induction. J Biol Chem 282, 15954-64 (2007) (Pubitemid 47100378)
2. S Chattopadhyay. S Bhattacharyya, B Saha. J Chakrabarty, S Mohanty. DMS Hossain, S Banerjee. K Das, G Sa, Das T: Tumor-shed PGE2 impairs IL2Rgcsignaling to inhibit CD4+ T cell survival: Regulation by theaflavins. PLoS One 4, e7382 (2009)
3. S Bhattacharyya. D Md. S Hossain, S Mohanty. GS Sen, S Chattopadhyay. S Banerjee, J Chakraborty. K Das, D Sarkar. T Das, G Sa: Curcumin reverses T cell-mediated adaptive immune dysfunctions in tumor-bearing host. Cell Mol Immunol 7, 306-315 (2010)
4. U Ritz. F Momburg, H Pilch. C Huber, M. Maeurer, B Seliger: Deficient expression of components of the MHC class I antigen processing machinery in human cervical carcinoma. Int J Oncol 19, 1211-20 (2001)
5. K Staveley-O'Carroll. E Sotomayor, J Montgomery: Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc Natl Acad Sci USA 95, 1178-83 (1998) (Pubitemid 28124932)
6. T Saito. G Dworacki, W Gooding. MT Lotze, TL Whiteside: Spontaneous apoptosis of CD8+ T lymphocytes in peripheral blood of patients with advanced melanoma. Clin Cancer Res 6, 1351-64 (2000) (Pubitemid 30226220)
7. L. Pekarek, B. Starr, A. Toledano, H Schreiber. Inhibition of tumor growth by elimination of granulocytes. J Exp Med 181, 435-40 (1995)
8. T. Curiel, G Coukos, L Zou: Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 10, 942-9 (2004) (Pubitemid 39273735)
9. TL Whiteside: The tumor microenvironment and its role in promoting tumor growth. Oncogene 27, 5904-12 (2008)
10. F. Crespo, X Sun. JG Cripps, R Fernandez-Botran: The immunoregulatory effects of gangliosides involve immune deviation favoring type-2 T cell responses. J Leukoc Biol 79, 586-95 (2006) (Pubitemid 44831235)
11. J Cunliffe: Tissue homeostasis and immunity-more on models. Scand J Immunol 64, 172-6 (2006)
12. K. de Visser, A Eichten, LM Coussens: Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 6, 24-37 (2006) (Pubitemid 43053650)
13. K Minkis. DG Kavanagh, G Alter. D Bogunovic, D O'Neill. S Adams, A Pavlick. BD Walker, M. Brockman, R. Gandhi, N Bhardwaj: Type 2 Bias of T cells expanded from the blood of melanoma patients switched to type 1 by IL-12p70 mRNA-transfected dendritic cells. Cancer Res 68, 9441-50 (2008)
14. T Kikuchi. S Uehara, H Ariga. T Tokunaga, A Kariyone. T Tamura, K Takatsu: Augmented induction of CD8+ cytotoxic T-cell response and antitumour resistance by T helper type 1-inducing peptide. Immunology 117, 47-58 (2006)
15. F Masson, GT Belz: Mobilizing forces-CD4+ helper T cells script adaptive immunity. Cell Res 20, 1-3 (2010)
16. Y Nakanishi. B Lu, C Gerard, A Iwasaki: CD8+ T lymphocyte mobilization to virus-infected tissue requires CD4+ T-cell help. Nature 462, 510-513 (2009)
17. S. Gaffen, G Hajishengallis: A new inflammatory cytokine on the block: re-thinking periodontal disease and the Th1/Th2 paradigm in the context of Th17 cells and IL-17. J Dent Res 87, 817-28 (2008)
18. G Canderan, P Dellabona: T helper 17 T cells do good for cancer immunotherapy. Immunotherapy 2, 21-4 (2010)
19. J. Rolland, L. Gardner, RE O'Hehir: Functional regulatory T cells and allergen immunotherapy. Curr Opin Allergy Clin Immunol 10, 559-66 (2010)
20. M. Curotto de Lafaille, JJ Lafaille: Natural and adaptive foxp3+ regulatory T cells: more of the same or a division of labor? Immunity 30, 626-35 (2009)
21. A Merlo. P Casalini, M. Carcangiu, C Malventano. T Triulzi, S Mènard. E Tagliabue, A Balsari: FOXP3 expression and overall survival in breast cancer. J Clin Oncol 27, 1746-52 (2009)
22. K. Shafer-Weaver, M. Anderson, K Stagliano. A Malyguine, N. Greenberg, AA Hurwitz: Cutting Edge: Tumor-specific CD8+ T cells infiltrating prostatic tumors are induced to become suppressor cells. J Immunol 183, 4848-52 (2009)
23. N Chaput. S Louafi, A Bardier. F Charlotte, J. Vaillant, F Ménégaux. M Rosenzwajg, F Lemoine. D Klatzmann, J Taieb: Identification of CD8+CD25+Foxp3+ suppressive T cells in colorectal cancer tissue. Gut 58, 520-9 (2009)
24. A Hamaï. H Benlalam, F Meslin. M Hasmim, T Carré. I Akalay, B Janji. G Berchem, M. Noman, S Chouaib: Immune surveillance of human cancer: if the cytotoxic T-lymphocytes play the music, does the tumoral system call the tune? Tissue Antigens 75, 1-8 (2010)
25. A. Mailloux, MR Young. Regulatory T-cell trafficking: from thymic development to tumor-induced immune suppression. Crit Rev Immunol 30, 435-47 (2010)
26. S Nagaraj, DI Gabrilovich: Myeloid-derived suppressor cells in human cancer. Cancer J 16, 348-53 (2010)
27. C. Fraser, M. Brown, K. Diener, JD Hayball: Unravelling the complexity of cancer-immune system interplay. Expert Rev Anticancer Ther 10, 917-34 (2010)
28. B Frankenberger. E Noessner, DJ Schendel: Immune suppression in renal cell carcinoma. Semin Cancer Biol 17, 330-43 (2007) (Pubitemid 47211966)
29. M Iero. R Valenti, V Huber. P Filipazzi, G Parmiani. S Fais, L Rivoltini: Tumour-released exosomes and their implications in cancer immunity. Cell Death Differ 15, 80-8 (2008) (Pubitemid 350286175)
30. L Rivoltini. P Canese, V Huber. M Iero, L Pilla. R Valenti, S Fais. F Lozupone, C Casati. C Castelli, G Parmiani: Escape strategies and reasons for failure in the interaction between tumour cells and the immune system: how can we tilt the balance towards immune-mediated cancer control? Expert Opin Biol Ther 5, 463-76 (2005) (Pubitemid 40593331)
31. S Biswas. K Biswas, A Richmond. J Ko, S Ghosh. M Simmons, P Rayman. B Rini, I Gill. CS Tannenbaum, JH Finke: Elevated levels of select gangliosides in T cells from renal cell carcinoma patients is associated with T cell dysfunction. J Immunol 183, 5050-8 (2009)
32. J. Park, D. Wu, M Prendes. SX Lu, G Ragupathi. N Schrantz, PB Chapman: Fine specificity of natural killer T cells against GD3 ganglioside and identification of GM3 as an inhibitory natural killer T-cell ligand. Immunology 123, 145-55 (2008) (Pubitemid 350256006)
33. M. Fuster, JD Esko: The sweet and sour of cancer: glycans as novel therapeutic targets Nat Rev Cancer 5, 526-42 (2005) (Pubitemid 40942829)
34. S Sonnino, A Prinetti: Gangliosides as regulators of cell membrane organization and functions. Adv Exp Med Biol 688, 165-84 (2010)
35. A d'Azzo. A Tessitore, R Sano: Gangliosides as apoptotic signals in ER stress response. Cell Death Differ 13, 404-14 (2006)
36. A Huwiler. T Kolter, J Pfeilschifter, K Sandhoff: Physiology and pathophysiology of sphingolipid metabolism and signaling. Biochim Biophys Acta 1485, 63-99 (2000) (Pubitemid 30314727)
37. G Tettamanti: Ganglioside/glycosphingolipid turnover: new concepts. Glycoconj J 20, 301-17 (2004) (Pubitemid 39024039)
38. E Bieberich. T Tencomnao, D Kapitonov, RK Yu: Effect of N-glycosylation on turnover and subcellular distribution of N-acetylgalactosaminyltransferase I and sialyltransferase II in neuroblastoma cells. J Neurochem 74, 2359-64 (2000) (Pubitemid 30314211)
39. E Bieberich. S MacKinnon, J Silva. DD Li, T Tencomnao. L Irwin, D Kapitonov, RK Yu: Regulation of ganglioside biosynthesis by enzyme complex formation of glycosyltransferases. Biochemistry 41, 11479-87 (2002)
40. H. Choi, T. Chung, S. Kang, Y. Lee, J. Ko, J. Kim, CH Kim: Ganglioside GM3 modulates tumor suppressor PTEN-mediated cell cycle progression- transcriptional induction of p21 (WAF1) and p27 (kip1) by inhibition of PI-3K/AKT pathway. Glycobiology 16, 573-83 (2006) (Pubitemid 43985498)
41. M Heffer-Lauc. G Lauc, L Nimrichter. SE Fromholt, RL Schnaar: Membrane redistribution of gangliosides and glycosylphosphatidylinositol-anchored proteins in brain tissue sections under conditions of lipid raft isolation. Biochim Biophys Acta 1686, 200-208 (2005) (Pubitemid 40039147)
42. T Yamashita. R Wada, T Sasaki. C Deng, U Bierfreund. K Sandhoff, RL Proia: A vital role for glycosphingolipid synthesis during development and differentiation. Proc Natl Acad Sci U S A 96, 9142-7 (1999) (Pubitemid 29374721)
43. S Hakomori: Tumor malignancy defined by aberrant glycosylation and sphingo (glyco) lipid metabolism. Cancer Res 56, 5309-18 (1996) (Pubitemid 27011703)
44. C. Pukel, K. Lloyd, L. Travassos, W. Dippold, H. Oettgen, LJ Old: GD3, a prominent ganglioside of human melanoma. Detection and characterisation by mouse monoclonal antibody. J Exp Med 155, 1133-47 (1982) (Pubitemid 12142729)
45. S Birklé. G Zeng, L Gao. RK Yu, J Aubry: Role of tumor-associated gangliosides in cancer progression. Biochimie 85, 455-63 (2003) (Pubitemid 36626016)
46. K. Furukowa, Gangliosides in melanoma. In: Springer-Verlag, Eds: K Furukowa and K. O Lloyd, Heildeberg (1990)
47. J. Carubia, R. Yu, L. Macala, J. Kirkwood, JM Varga: Gangliosides of normal and neoplastic human melanocytes. Biochem Biophys Res Commun 120, 500-504 (1984) (Pubitemid 14149541)
48. M. Ravindranath, T Tsuchida. DL Morton, RF Irie: Ganglioside GM3:GD3 ratio as an index for the management of melanoma. Cancer 67, 3029-3035 (1991)
49. A Merzak. S Koochekpour, GJ Pilkington: Cell surface gangliosides are involved in the control of human glioma cell invasion in vitro. Neurosci Lett 177, 44-46 (1994) (Pubitemid 24269425)
50. SI Hakomori: Inaugural article: the glycosynapse. Proc Natl Acad Sci USA 99, 225-232 (2002)
51. Y Kong. R Li, S Ladisch: Natural forms of shed tumor gangliosides. Biochim Biophys Acta 1394, 43-56 (1998) (Pubitemid 28451575)
52. V Dolo. R Li, M Dillinger. S Flati, J Manel. BJ Taylor, A Pavan, S Ladisch: Enrichment and localization of ganglioside G (D3) and caveolin-1 in shed tumor cell membrane vesicles. Biochim Biophys Acta 1486, 265-274 (2000) (Pubitemid 30618866)
53. M Rusnati. E Tanghetti, C Urbinati. G Tulipano, S Marchesini. M Ziche, M Presta: Interaction of fibroblast growth factor-2 (FGF-2) with free gangliosides: biochemical characterization and biological consequences in endothelial cell cultures. Mol Biol Cell 10, 313-327 (1999) (Pubitemid 29156475)
54. F Chang. R Li, S Ladisch: Shedding of gangliosides by human medulloblastoma cells. Exp Cell Res 234, 341-346 (1997) (Pubitemid 27335176)
55. L. RX, S Ladisch: Shedding of human neuroblastoma gangliosides. Biochim Biophys Acta 1083, 57-64 (1991)
56. R Bjerkvig. O Engebraaten, O. Laerum, P Fredman. L Svennerholm, F. Vrionis, CJ Wikstrand and DD Bigner: Anti-GM2 monoclonal antibodies induce necrosis in GM2-rich cultures of a human glioma cell line. Cancer Res 51, 4643-4648 (1991)
57. W. Dippold, A Knuth and KH Meyer zum Buschenfelde: Inhibition of human melanoma cell growth in vitro by monoclonal anti-GD3-ganglioside antibody. Cancer Res 44, 806-810 (1984) (Pubitemid 14184622)
58. A. Houghton, D Mintzer. C Cordon-Cardo, S Welt. B Fliegel, S Vadhan. E Carswell, M. Melamed, H. Oettgen, LJ Old: Mouse monoclonal IgG3 antibody detecting GD3 ganglioside: a phase I trial in patients with malignant melanoma. Proc Natl Acad Sci USA 82, 1242-1246 (1985) (Pubitemid 15100531)
59. S Yoshida. S Fukumoto, H Kawaguchi. S Sato, R Ueda, K Furukawa: Ganglioside, (GD2) in small cell lung cancer cell lines: enhancement of cell proliferation and mediation of apoptosis. Cancer Res 51, 4244-4252 (2001) (Pubitemid 32720995)
60. PH Black: Shedding from normal and cancer-cell surfaces. N Engl J M 303, 1415-1416 (1980) (Pubitemid 11197535)
61. R Olshefski, S Ladisch: Intercellular transfer of shed tumor cell gangliosides. FEBS Lett 386, 11-14 (1996) (Pubitemid 26143791)
62. D Kudo. P Rayman, C Horton. MK Cathcart, R. Bukowski, M Thornton. C Tannenbaum, JH Finke: Gangliosides expressed by the renal cell carcinoma cell line SK-RC-45 are involved in tumor-induced apoptosis of T cells. Cancer Res 63, 1676-1683 (2003) (Pubitemid 36373661)
63. R McKallip. R Li, S Ladisch: Tumor gangliosides inhibit the tumor-specific immune response. J Immunol 163, 3718-3726 (1999) (Pubitemid 29450894)
64. S Ladisch. H Becker, L Ulsh: Immunosuppression by human gangliosides: Relationship of carbohydrate structure to the inhibition of T cell responses. Biochim. Biophys. Acta 1125, 180-188 (1992).
65. S Ladisch. R Li, E Olson: Ceramide structure predicts tumor ganglioside immunosuppressive activity. Proc Natl Acad Sci USA 91, 1974-1978 (1994). (Pubitemid 24080329)
66. A. Bharti, SM Singh: Gangliosides derived from a T cell lymphoma inhibit bone marrow cell proliferation and differentiation. Int Immunopharmacol 1, 155-165 (2001) (Pubitemid 32193610)
67. C Dumontet. A Rebbaa, J Bienvenu, J Portoukalian: Inhibition of immune cell proliferation and cytokine production by lipoprotein-bound gangliosides. J Cancer Immunol Immunother 38, 311-316 (1994) (Pubitemid 24128009)
68. R. Lan, C Selmi, ME Gershwin: The regulatory, inflammatory, and T cell programming roles of interleukin-2 (IL-2). J Autoimmun 31, 7-12 (2008) Review
69. W. Merritt, J. Bailey, DH Pluznik: Inhibition of interleukin-2-dependent cytotoxic T-lymphocyte growth by gangliosides. Cell Immunol 89, 1-10 (1984) (Pubitemid 15208162)
70. J. Chu, FJ Sharom Gangliosides inhibit Tlymphocyte proliferation by preventing the interaction of interleukin-2 with its cell surface receptors. Immunology 79, 10-17 (1993) (Pubitemid 23151187)
71. G. Dbaibo, M. Pushkareva, S Jayadev. JK Schwarz, J. Horowitz, L. Obeid, YA Hannun: Retinoblastoma gene product as a downstream target for a ceramidedependent pathway of growth arrest. Proc Natl Acad Sci U S A 92, 1347-1351 (1995)
72. J Péguet. M Sportouch, I Popa. O Berthier, D Schmitt, J Portoukalian: Gangliosides from human melanoma tumors impair dendritic cell differentiation from monocytes and induce their apoptosis. J Immunol 170, 3488-3494 (2003) (Pubitemid 36359214)
73. H Sietsma. W Nijhof, B Dontje. E Vellenga, W. Kamps, JW Kok: Inhibition of hemopoiesis in vitro by neuroblastoma-derived gangliosides. Cancer Res 58, 4840-4844 (1998) (Pubitemid 28503679)
74. DR Goldstein: Toll like receptors and acute allograft rejection. Transpl Immunol 17, 11-15 (2006) Review (Pubitemid 44828796)
75. W Shen. K Stone, A Jales. D Leitenberg, S Ladisch S: Inhibition of TLR activation and up-regulation of IL-1R-associated kinase-M expression by exogenous gangliosides. J Immunol 180, 4425-4432 (2008)
76. A Heitger, S Ladisch: Gangliosides block antigen presentation by human monocytes. Biochim Biophys Acta 1303, 161-168 (1996) (Pubitemid 26325547)
77. A Jales. R Falahati, E Mari. EJ Stemmy, W Shen. C Southammakosane, D Herzog. S Ladisch, D Leitenberg: Ganglioside-exposed dendritic cells inhibit T-cell effector function by promoting regulatory cell activity. Immunology 132, 134-143 (2011)
78. P Novy. M Quigley, X Huang, Y Yang: CD4 T cells are required for CD8 T cell survival during both primary and memory recall responses. J Immunol 179, 8243-8251 (2007)
79. H Huang. S Hao, F Li. Z Ye, J Yang, J Xiang: CD4+ Th1 cells promote CD8+ Tc1 cell survival, memory response, tumor localization and therapy by targeted delivery of interleukin 2 via acquired pMHC I complexes. Immunology 120, 148-159 (2007) (Pubitemid 46046315)
80. P Rayman. AK Wesa, A. Richmond, T Das. K Biswas, G Raval. WJ Storkus, C Tannenbaum. A Novick, R Bukowski, J Finke: Effect of renal cell carcinomas on the development of type 1 T-cell responses. Clin Cancer Res 10 6360S-6366S (2004) (Pubitemid 39287492)
81. D. Irani, K. Lin, DE Griffin: Brain-derived gangliosides regulate the cytokine production and proliferation of activated T cells. J Immunol 157, 4333-4340 (1996) (Pubitemid 126449350)
82. L. R, N Villacreses, S Ladisch: Human tumor gangliosides inhibit murine immune responses in vivo. Cancer Res 55, 211-214 (1995)
83. J. Zou, L. Morford, C Chougnet. AR Dix, A. Brooks, N Torres. JD Shuman, J. Coligan, W. Brooks, T. Roszman, GM Shearer: Human glioma-induced immunosuppression involves soluble factor (s) that alters monocyte cytokine profile and surface markers. J Immunol 162, 4882-4892 (1999) (Pubitemid 29314893)
84. G. Martinez, R. Nurieva, X. Yang, C Dong: Regulation and function of proinflammatory TH17 cells. Ann N Y Acad Sci 1143, 188-211 (2008)
85. N Martin-Orozco. Muranski P, Chun. Y, Yan. XO, Yamazak. T, L. S, Hw. P, Restif. NP, Overwij. WW, Dong C. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity. 2009 Nov. 20; 31(5):787-98.
86. G Canderan, P Dellabona: T helper 17 T cells do good for cancer immunotherapy. Immunotherapy 2, 21-24 (2010)
87. M Kortylewski, H Yu: Role of Stat3 in suppressing anti-tumor immunity. Curr Opin Immunol 20, 228-233 (2008) Review
88. J. Gnerlich, J. Mitchem, J. Weir, N. Sankpal, H Kashiwagi. BA Belt, M. Porembka, J. Herndon, T. Eberlein, P Goedegebuure, DC Linehan: Induction of Th17 cells in the tumor microenvironment improves survival in a murine model of pancreatic cancer. J Immunol 185, 4063-4071 (2010)
89. R. Flavell, Sanjab. S, Wrzesinsk. SH, Licona-Limón P. The polarization of immune cells in the tumour environment by TGFbeta. Nat Rev Immunol 2010 Aug; 10(8):554-67.
90. F Korangy. B Höchst, M. Manns, TF Greten: Immunotherapy of hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 4, 345-353 (2010) Review
91. L Li. SP Li, J Min, L Zheng: Hepatoma cells inhibit the differentiation and maturation of dendritic cells and increase the production of regulatory T cells. Immunol Lett 114, 38-45 (2007) (Pubitemid 47625596)
92. J Souady. M Hülsewig, U Distler. J Haier, A Denz. C Pilarsky, N Senninger. K Dreisewerd, J Peter, J Müthing: Differences in CD75s-and iso-CD75s-ganglioside content and altered mRNA expression of sialyltransferases ST6GAL1 and ST3GAL6 in human hepatocellular carcinoma and non-tumoral liver tissues. Glycobiology (2010) [Epub ahead of print]
93. J Wang. ZH Lu, H. Gabius, C Rohowsky. RW Ledeen, G Wu: Cross-linking of GM1 ganglioside by galectin-1 mediates regulatory T cell activity involving TRPC5 channel activation: possible role in suppressing experimental autoimmune encephalomyelitis. J Immunol 182, 4036-4045 (2009)
94. Q Xie. L Gan, J Wang. I Wilson, L Li: Loss of the innate immunity negative regulator IRAK-M leads to enhanced host immune defense against tumor growth. Mol Immunol 44, 3453-3461 (2007) (Pubitemid 46754450)
95. Y Adachi. N Oyaizu, S Than. TW McCloskey, S Pahwa: IL-2 rescues in vitro lymphocyte apoptosis in patients with HIV infection: correlation with its ability to block culture-induced down-modulation of Bcl-2. J Immunol 157, 4184-4193 (1996) (Pubitemid 126449333)
96. M Weller. U Malipiero, P Groscurth, A Fontana: T cell apoptosis induced by interleukin-2 deprivation or transforming growth factor-beta 2: modulation by the phosphatase inhibitors okadaic acid and calyculin A. Exp Cell Res 221, 395-403 (1995)
97. R. Sobol, D. Shawler, C Carson. C Van, D Mercola. H Fakhrai, M. Garrett, R Barone. P Goldfarb, R. Bartholomew, S Brostoff. DJ Carlo, I Royston, DP Gold: Interleukin 2 gene therapy of colorectal carcinoma with autologous irradiated tumor cells and genetically engineered fibroblasts: a Phase I study. Clin Cancer Res 5, 2359-2365 (1999) (Pubitemid 29437314)
98. J Zhang. T Bárdos, Q Shao. J Tschopp, K Mikecz. TT Glant, A Finnegan: IL-4 potentiates activated T cell apoptosis via an IL-2-dependent mechanism. J Immunol 170, 3495-3503 (2003) (Pubitemid 36359215)
99. M Zhu. MF Wei, F Liu. HF Shi, G Wang, S Chen: Allogeneic T-cell apoptosis induced by interleukin-10-modified dendritic cells: a mechanism of prolongation of intestine allograft survival? Transplant Proc 36, 2436-2447 (2004)
100. B Stockinger, M Veldhoen: Differentiation and function of Th17 T cells. Curr Opin Immunol 19, 281-286 (2007) (Pubitemid 46687011)
101. B Stockinger: Th17 cells: An orphan with influence. Immunol Cell Biol 85, 83-84 (2007) (Pubitemid 46398729)
102. P Pandiyan. L Zheng, S Ishihara. J Reed, MJ Lenardo: CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol 8, 1353-1362 (2007) (Pubitemid 350131172)
103. H Offner. T Thieme, AA Vandenbark: Gangliosides induce selective modulation of CD4 from helper T lymphocytes. J Immunol 139, 3295-3305 (1987) (Pubitemid 18021980)
104. K Biswas. A Richmond, P Rayman. S Biswas, M Thornton. G Sa, T Das. R Zhang, A Chahlavi. CS Tannenbaum, A Novick. R Bukowski, JH Finke: GM2 expression in renal cell carcinoma: potential role in tumorinduced T-cell dysfunction. Cancer Res 66, 6816-6825 (2006) (Pubitemid 44085642)
105. R McKallip. R Li, S Ladisch: Tumor gangliosides inhibit the tumor-specific immune response. J Immunol 163, 3718-3726 (1999) (Pubitemid 29450894)
106. D Banerjee. HC Liou, R Sen: c-Rel-dependent priming of naive T cells by inflammatory cytokines. Immunity 23, 445-458 (2005) (Pubitemid 41443445)
107. S Rao. S Gerondakis, D Woltring, MF Shannon: c-Rel is required for chromatin remodeling across the IL-2 gene promoter. J Immunol 170, 3724-3731 (2003) (Pubitemid 36359242)
108. R. Grumont, S Gerondakis: Murine c-rel transcription is rapidly induced in T-cells and fibroblasts by mitogenic agents and the phorbol ester 12-O-tetradecanoylphorbol-13-acetate. Cell Growth Differ 1, 345-350 (1990)
109. P Ghosh. TH Tan, N. Rice, A Sica, HA Young: The interleukin 2 CD28-responsive complex contains at least three members of the NF kappa B family: c-Rel, p50, and p65. Proc Natl Acad Sci USA 90, 1696-1700 (1993) (Pubitemid 23069923)
110. R. Uzzo, P. Clark, P Rayman. T Bloom, L Rybicki. AC Novick, R. Bukowski, JH Finke: Alterations in NFkappaB activation in T lymphocytes of patients with renal cell carcinoma. J Natl Cancer Inst 91, 718-721 (1999) (Pubitemid 29234567)
111. P Ghosh. A Sica, H. Young, J Ye. JL Franco, R. Wiltrout, D. Longo, N. Rice, KL Komschlies: Alterations in NF. B/Rel family proteins in splenic T-cells from tumor-bearing mice and reversal following therapy. Cancer Res 54, 2969-2972 (1994)
112. X Li. J Liu, J. Park, T. Hamilton, P Rayman. E Klein, R Tubbs. R Bukowski, J Finke: T cells from renal cell carcinoma patients exhibit an abnormal pattern of. Bspecific DNA binding activity, a preliminary report. Cancer Res 54, 5424-5429 (1994)
113. R. Uzzo, P Rayman. V Kolenko, P. Clark, M. Cathcart, T Bloom. AC Novick, R. Bukowski, T Hamilton, JH Finke: Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappaB activation in T cells. J Clin Invest 104, 769-776 (1999) (Pubitemid 29536362)
114. M. Thornton, D Kudo. P Rayman, C Horton. L Molto, M. Cathcart, C Ng. EP Kozik, R Bukowski. I Derweesh, C. Tannenbaum, JH Finke: Degradation of NFkappa B in T cells by gangliosides expressed on renal cell carcinomas. J Immunol 172, 3480-3490 (2004) (Pubitemid 38337928)
115. J. Finke, P Rayman. R George, C. Tannenbaum, V Kolenko. R Uzzo, A. Novick, RM Bukowski: Tumorinduced sensitivity to apoptosis in T cells from patients with renal cell carcinoma: role of nuclear factor-. B suppression. Clin Cancer Res 7, 940s-946s (2001) (Pubitemid 33600949)
116. D. Irani, K. Lin, DE Griffin: Brain-derived gangliosides regulate the cytokine production and proliferation of activated T cells. J Immunol 157, 4333-4340 (1996) (Pubitemid 126449350)
117. A Colell. C Garcia-Ruiz, J Roman. A Ballesta, JC Fernandez-Checa: Ganglioside GD3 enhances apoptosis by suppressing the nuclear factor-. B-dependent survival pathway. FASEB J 15, 1068-1070 (2001)
118. M Potapenko. GV Shurin, J de León: Gangliosides as immunomodulators. Adv Exp Med Biol 601, 195-203 (2007) Review.
119. D Kudo. P Rayman, C Horton. MK Cathcart, R. Bukowski, M Thornton. C Tannenbaum, JH Finke: Gangliosides expressed by the renal cell carcinoma cell line SK-RC-45 are involved in tumor-induced apoptosis of T cells. Cancer Res 63, 1676-1683, (2003) (Pubitemid 36373661)
120. C Garrido. L Galluzzi, M Brunet. PE Puig, C Didelot, G Kroemer: Mechanisms of cytochrome c release from mitochondria. Cell Death Differ 13, 1423-1433 (2006) (Pubitemid 44210346)
121. G Sa. T Das, C Moon. CM Hilston, P. Rayman, B. Rini, C. Tannenbaum, JH Finke: GD3, an overexpressed tumor-derived ganglioside, mediates the apoptosis of activated but not resting T cells. Cancer Res 69, 3095-3104 (2009)
122. B. Kristal, AM Brown: Apoptogenic ganglioside GD3 directly induces the mitochondrial permeability transition. J Biol Chem 274, 23169-23175 (1999).
123. C Ruiz. A Colell, R Paris, J Checa: Direct interaction of GD3 ganglioside with mitochondria generates reactive oxygen species followed by mitochondrial permeability transition, cytochrome c release, and caspase activation. FASEB J 14, 847-858 (2000) (Pubitemid 30241661)
124. T Das. G Sa, E Paszkiewicz. C Hilston, L Molto. P Rayman, D Kudo. K Biswas, R. Bukowski, J. Finke, CS Tannenbaum: Renal cell carcinoma tumors induce T cell apoptosis through receptor-dependent and receptorindependent pathways. J Immunol 180, 4687-4696 (2008)
125. T Das. G Sa, C Hilston. D Kudo, P Rayman. K Biswas, L Molto. R Bukowski, B Rini. JH Finke, C Tannenbaum: GM1 and TNFa, overexpressed in renal cell carcinoma, synergize to induce T cell apoptosis. Cancer Res 68, 2014-2023 (2008) (Pubitemid 351416589)
126. M. Ravindranath, Morton DL: Role of gangliosides in active immunotherapy with melanoma vaccine. Int Rev Immunol 7, 303-329 (1991)
127. R. Bitton, Guthman. MD, Gabr. MR, Carner. AJ, Alons. DF, Fainboi. L, Gomez DE: Cancer vaccines: an update with special focus on ganglioside antigens. Oncol Rep 9, 267-276 (2002)